The USFDA has issued a warning letter to Jagsonpal Pharmaceuticals for significant manufacturing lapses at its ...

Glucagon-like peptide 1 (GLP-1) drugs, such as Ozempic, are intended for type 2 diabetes patients and people with obesity, and have become wildly popular with the general population for weight loss.